rs2073618
rs2073618 · 4 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | rs2073618 | “Following six months of ibandronate treatment, the AA genotype of rs3134069, TT, TC genotypes of rs3102735, GG, and GC genotypes of rs2073618 SNP showed a significant increase in OPG levels.” | 0.90 | hgvs_regex_v1 |
| variant | rs2073618 | “RANKL (rs9533156) and OPG (rs2073618, rs3102735) polymorphisms were genotyped in genomic DNA, using Tetra-ARMS PCR protocol.” | 0.90 | hgvs_regex_v1 |
| variant | rs2073618 | “The frequency distribution of the heterozygous CG genotype of rs2073618 (OPG) was lower in the OP (36.8%) than in CTRs (47%) (OR: 0.6, 95% CI: 0.3-0.97; p = 0.041).” | 0.90 | hgvs_regex_v1 |
| variant | rs2073618 | “Genetic variants of RANK (rs1805034 and rs35211496), RANKL (rs2277438 and rs9533156), and OPG (rs2073618 and rs3102735) were genotyped using RT-PCR.” | 0.90 | hgvs_regex_v1 |